Apimostinel is under clinical development by Gate Neurosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Apimostinel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apimostinel overview

Apimostinel (NRX-1074, AGN-241660) is under development for the treatment of acute sever major depressive disorder. The drug candidate is administered through intravenous route. NRX-1074, is NMDAR partial agonist. NRX-1074 is based on NMDAR modulation platform, comprising novel patented chemistry classes with key molecular features.

It was also under development for major depressive disorder. It was administered through oral route.

Gate Neurosciences overview

Gate Neurosciences offer neuroscience-related medical services. IT is headquartered in Carmel, Indiana, the US.

For a complete picture of Apimostinel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.